Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.32 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7029611 | 0.79 | KCNA5 (0.38) | NPC1RAB9ASMN1; SMN2HTTCYP1A2 | |
| SCHEMBL7031781 | 0.78 | CYP1A2 (0.36) | CYP1A2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL7031343 | 0.76 | LMNA (0.40) | NPC1RAB9ASMN1; SMN2HTTCYP1A2 | |
| SCHEMBL7032571 | 0.76 | CYP1A2 (0.41) | NPC1RAB9ASMN1; SMN2HTTCYP1A2 | |
| SCHEMBL7158601 | 0.75 | MEN1 (0.39) | NPC1RAB9ASMN1; SMN2CYP1A2MEN1 | |
| SCHEMBL7031899 | 0.75 | SMN1; SMN2 (0.43) | NPC1RAB9ASMN1; SMN2HTTCYP1A2 | |
| SCHEMBL7033054 | 0.74 | LMNA (0.41) | NPC1RAB9ASMN1; SMN2HTTCYP1A2 | |
| SCHEMBL7153820 | 0.74 | ALDH1A1 (0.42) | SMN1; SMN2HTTCYP1A2HIF1AKDM4E | |
| SCHEMBL7032030 | 0.74 | RAB9A (0.40) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL7027980 | 0.74 | TDP1 (0.34) | NPC1RAB9ASMN1; SMN2HTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030139600-A1 | 2-pyridylsilane, processes for producing and using the same | SUMITOMO CHEMICAL CO., LTD. | 2003-07-24 | — | — | US | disclosed |
| US-6548673-B1 | Alkylation using transition metal complex catalyst; purified by acid/base extraction | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-04-15 | — | — | US | disclosed |
| US-6531602-B2 | Desilylation of a 2-pyridylsilane to form an alcohol | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-03-11 | — | — | US | disclosed |
| US-20020165397-A1 | 2-Pyridylsilane, processes for producing and using the same | SUMITOMO CHEMICAL CO., LTD. | 2002-11-07 | — | — | US | disclosed |
| EP-1035125-A2 | 2-Pyridylsilane, processes for producing and using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165397-A1 | 2-Pyridylsilane, processes for producing and using the same | H1-0, RIOK2, H1-4 | NPC1 2751/4885RAB9A 112/4885SMN1; SMN2 1549/4885 |
| US-20030139600-A1 | 2-pyridylsilane, processes for producing and using the same | H1-0, H1-4, H1-2 | NPC1 2839/4885RAB9A 110/4885SMN1; SMN2 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.